Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2018  |  Volume : 14  |  Issue : 1  |  Page : 163-170

Medical expenditure for liver cancer in urban China: A 10-year multicenter retrospective survey (2002–2011)


1 Public Health Information Research Office, Institute of Medical Information, Chinese Academy of Medical Sciences, Beijing, P. R. China
2 Program Office for Cancer Screening in Urban China, Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, National Cancer Center of China, No. 17 Panjiayuannanli, Chaoyang District, Beijing, P. R. China
3 Department of Cancer Epidemiology, Henan Office for Cancer Control and Research, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, No. 127 Dongming Road, Zhengzhou, Henan, P. R. China
4 Department of Human Resources, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, P. R. China
5 Department of Health Economics, School of Health Management, Harbin Medical University, Harbin, Heilongjiang, P. R. China
6 Institute of Epidemiology and Health Statistics, Lanzhou University, Lanzhou, Gansu, P. R. China
7 Center for Health Management and Policy, Key Lab of Health Economics and Policy, Shandong University, Jinan, Shandong, P. R. China
8 Science and Education Department of Public Health Division, Shandong Tumor Hospital, Jinan, Shandong, P. R. China
9 Teaching and Research Department, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, Xinjiang, P. R. China
10 Zhejiang Office for Cancer Control and Research, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, P. R. China
11 Chongqing Office for Cancer Control and Research, Chongqing Cancer Hospital, Chongqing, P. R. China
12 Liaoning Office for Cancer Control and Research, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, P. R. China
13 Heilongjiang Office for Cancer Control and Research, Affiliated Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang, P. R. China
14 Cancer Epidemiology Research Center, Gansu Provincial Cancer Hospital, Lanzhou, Gansu, P. R. China
15 Department of Control and Prevention of Chronic Non-Communicable Diseases, Xuzhou Center for Disease Control and Prevention, Xuzhou 221006, Jiangsu, P. R. China
16 Ningbo Clinical Cancer Prevention Guidance Center, Ningbo No. 2 Hospital, Ningbo, Zhejiang, P. R.C Shandong, P. R. China
17 Health Department of Kailuan Group, Kailuan General Hospital, Tangshan, Hebei, P. R. China
18 Department of Health Policy and Economic Research, Guangdong Provincial Institute of Public Health, Guangzhou, Guangdong, P. R. China
19 Department of Occupational Medicine, Tangshan People's Hospital, Tangshan, Hebei, P. R. China
20 Institute of Chronic Disease Prevention and Control, Harbin Center for Disease Control and Prevention, Harbin, Heilongjiang, P. R. China
21 Urban Office of Cancer Early Detection and Treatment, Tieling Central Hospital, Tieling, Liaoning, P. R. China

Correspondence Address:
Associate Prof. A-Yan Mao
Institute of Medical Information, Chinese Academy of Medical Sciences; 3 Yabao Road, Chaoyang District, Beijing, 100020
P. R. China
Dr. Ju-Fang Shi
National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical School; No.17 Panjiayuannanli, Chaoyang District, Beijing
P. R. China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jcrt.JCRT_709_16

Rights and Permissions

Objective: This study aims to understand the medical expenditure for liver cancer during 2002-2011 in urban areas of China. Materials and Methods: This is a retrospective study. Based on a stratified cluster sampling method, a medical expenditure survey collected basic personal information from related medical records. Two-tailed independent sample t-test, variance analysis, and Student–Newman–Keuls Tests were used in cost analysis for the corresponding data types. Results: A total of 12,342 liver cancer patients were included in the analysis. Overall average medical expenditure per case for liver cancer diagnosis and treatment in China has increased from ¥21, 950 to ¥40, 386 over the study period. For each liver cancer patient diagnosed between 2009 and 2011, the average expenditures were 29,332 CNY for stage I, 35,754 CNY for stage II, 34,288 CNY for stage III, and 30,275 CNY for stage IV diseases (P < 0.001). Pharmaceuticals accounted for the biggest part of the medical expenditure and it rose from 48.01% to 52.96% during these ten years, and the share of nursing fee expenses was the lowest (around 1%). Over the entire 10-year data period, the per capita expenditure of the east region (32,983 CNY) was higher than that of the west region (26,219 CNY) and slightly higher than the central region (31,018 CNY, P < 0.001). Discussion: As a major cancer in China, liver cancer accounts for a large portion of health economic burden and its medical expenditure is heavy for families. Early diagnosis and treatment for liver cancer will save medical expenditure. Conclusion: The economic burden of liver cancer is high in China and related medical expenditure has increased.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed4016    
    Printed45    
    Emailed0    
    PDF Downloaded80    
    Comments [Add]    

Recommend this journal